BridgeMD
Cangrelor in endovascular stroke treatment with emergent carotid artery stenting (CANCAS)
EU CTIS ID: 2025-521564-35-00
What this study is testing
To assess the safety and efficacy of IV Cangrelor in patients with acute ischaemic stroke and large vessel occlusion of the intracranial carotid artery or first two segments of the middle cerebral artery (carotid artery territory) and concomitant symptomatic atherosclerotic extracranial carotid artery stenosis (≥50%) requiring mechanical thrombectomy and emergent extracranial carotid artery stenting.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients (≥18 years of age)
- Large vessel occlusion stroke of the anterior cerebral circulation (carotid artery territory)
- Concomitant ipsilateral atherosclerotic carotid artery stenosis ≥50% requiring mechanical thrombectomy and emergent carotid artery stenting
You likely can't join if
- Non-atherosclerotic carotid artery stenosis (e.g. dissection)
- Active pre-treatment with a P2Y12 inhibitor (e.g. Clopidogrel, Ticagrelor, Prasugrel
- Pre-treatment with oral anticoagulants in a therapeutic dosage
- Known pregnancy (for women with childbearing potential a negative pregnancy test is required)
- High intra- or extracranial bleeding risk according to the judgement of the treating stroke physicians (history of severe bleeding disorders, known haemophilia, severe liver disease, thrombocytopenia <100,000/µL, coagulation factor abnormalities, recent major surgery, recent major trauma, large brain infarct size
- Uncontrolled hypertension
See the full eligibility criteria
- Adult patients (≥18 years of age)
- Large vessel occlusion stroke of the anterior cerebral circulation (carotid artery territory)
- Concomitant ipsilateral atherosclerotic carotid artery stenosis ≥50% requiring mechanical thrombectomy and emergent carotid artery stenting
- Non-atherosclerotic carotid artery stenosis (e.g. dissection)
- Active pre-treatment with a P2Y12 inhibitor (e.g. Clopidogrel, Ticagrelor, Prasugrel
- Pre-treatment with oral anticoagulants in a therapeutic dosage
- Known pregnancy (for women with childbearing potential a negative pregnancy test is required)
- High intra- or extracranial bleeding risk according to the judgement of the treating stroke physicians (history of severe bleeding disorders, known haemophilia, severe liver disease, thrombocytopenia <100,000/µL, coagulation factor abnormalities, recent major surgery, recent major trauma, large brain infarct size
- Uncontrolled hypertension
- The patient’s medical history reveals a known allergy to any of the medications being used or their constituents, or to medications with a similar chemical structure
- Prohibited concomitant therapies
- Simultaneous participation in another interventional clinical trial
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.